Visual and anatomical outcomes by q12w/q8w status in the HAWK and HARRIER studies of brolucizumab versus aflibercept in neovascular age-related macular degeneration

Peter K. Kaiser¹, Frank G. Holz², Adrian Koh³, Yuichiro Ogura⁴, Glenn J. Jaffe⁵, Ramin Tadayoni⁶, Ursula Schmidt-Erfurth⁷, Julie Clark⁸*, Carrie Murray⁸*, Kinfemichael Gedif⁸, Pravin Dugel⁹*

¹Cole Eye Institute, Cleveland Clinic, Cleveland, USA; ²Department of Ophthalmology, University of Bonn, Bonn, Germany; ³Eye and Retina Surgeons, Camden Medical Centre, Singapore; ⁴Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan; ⁵Duke University, Durham, USA; ⁶Université de Paris, Ophthalmology Department, AP-HP, Hôpital Lariboisière, Paris, France; ⁷Medical University of Vienna, Vienna, Austria; ⁸Novartis Pharma AG, East Hanover, USA; ⁹Retinal Consultants of Arizona, Phoenix, USA

*Affiliation at the time the study was conducted

Retina Society Annual Meeting, September 2020
Disclosures

Peter K. Kaiser

Frank G. Holz
• Grants: Bayer, Centervue, Genentech/Roche, Heidelberg Engineering, Novartis, Zeiss; Consultant: Acucela, Alcon, Bayer, Boehringer-Ingehelm, Galimedix, Genentech, Heidelberg Engineering, Lin-Bioscience, Khanghong, Oxurion, Novartis, Roche, Zeiss

Adrian Koh
• Consultancy fees and honoraria from Novartis

Yuichiro Ogura
• Alcon, Astellas, Bayer, Boehringer Ingelheim, Kowa, Janssen, Nikon Healthcare Japan, Novartis, Otsuka, Santen, Senju, Sanwakagaku, Topcon, Wakamoto

Glenn J. Jaffe
• Iveric, Neurotech, Noveome, Novartis, Regeneron

Ramin Tadayoni
• Receipt of grants/research support from Allergan, Bayer, Optovue, Novartis, Zeiss; receipt of honoraria or consultation fees from Alcon, Allergan, Bayer, Genentech, Novartis, Oculis, Roche, Théa

Ursula Schmidt-Erfurth
• Consultant for Genentech, Heidelberg Engineering, Kodiak, Novartis, RetInSight, Roche

Julie Clark
• Employee of Novartis Pharma AG at time of study

Carrie Murray
• Employee of Novartis Pharma AG at time of study

Kinfemichael Gedif
• Employee of Novartis Pharma AG

Pravin Dugel
Summary

- HAWK and HARRIER: brolucizumab q12w/q8w met the primary endpoint of non-inferiority to aflibercept q8w in BCVA change from baseline to Week 48; BCVA gain was maintained through Week 96

- Brolucizumab subgroups with lesser or greater treatment need were identified based on masked investigators’ disease assessments

- Further analyses to compare brolucizumab and aflibercept-treated eyes with lesser or greater treatment need were conducted by applying equal criteria
  - Similar BCVA outcomes were seen for brolucizumab- and aflibercept-treated eyes with greater treatment need to the primary endpoint at Week 48, with a numerical advantage for brolucizumab towards Week 96; greater CST reductions were observed for brolucizumab versus aflibercept
  - BCVA and CST outcomes were comparable for brolucizumab- and aflibercept-treated eyes with lesser treatment need, with most brolucizumab patients on a q12w regimen

BCVA, best-corrected visual acuity; CST, central subfield thickness; q8w, 8-week dosing interval; q12w, 12-week dosing interval
HAWK and HARRIER: brolucizumab (q12w/q8w) vs aflibercept (q8w)\textsuperscript{1,2}

<table>
<thead>
<tr>
<th>Week</th>
<th>0</th>
<th>4</th>
<th>8</th>
<th>12</th>
<th>16</th>
<th>20</th>
<th>24</th>
<th>28</th>
<th>32</th>
<th>36</th>
<th>40</th>
<th>44</th>
<th>48</th>
<th>52</th>
<th>56</th>
<th>60</th>
<th>64</th>
<th>68</th>
<th>72</th>
<th>76</th>
<th>80</th>
<th>84</th>
<th>88</th>
<th>92</th>
<th>96</th>
</tr>
</thead>
<tbody>
<tr>
<td>brolucizumab 3/6 mg</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td></td>
<td></td>
</tr>
<tr>
<td>aflibercept 2 mg</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Matched phase

Maintenance phase: aflibercept (q8w) brolucizumab (q12w/q8w)

Disease activity assessment by masked investigators\textsuperscript{a}

*If disease activity was detected at any DAA visit, patients on brolucizumab q12w were adjusted to, and remained on, a q8w regimen

\textsuperscript{a}Disease activity assessments were conducted at pre-specified visits by the masked investigator. Presence of disease activity was determined at the discretion of the masked investigator and supported by protocol guidance based on dynamic functional and anatomical characteristics. Additional assessments and potential dosing interval adjustments occurred at Weeks 28, 40, 52, 64, 76, and 88 in HARRIER only. Sham injections were administered to maintain masking. Visual and anatomic assessments were made prior to injections at Weeks 16 and 48. DAA, disease activity assessment; q8w, 8-week dosing interval; q12w, 12-week dosing interval.
BCVA change from baseline to Week 96: brolucizumab versus aflibercept\textsuperscript{1,2}

![Graph showing BCVA change from baseline to Week 96 for brolucizumab 3 mg, brolucizumab 6 mg, and aflibercept 2 mg. The primary endpoint was met at Week 48.](image-url)


Full Analysis Set, LOCF. Non-inferiority (NI) margin = 4 letters. Analyzed using ANOVA model with baseline BCVA categories (≤55, 56–70, ≥71 letters), age categories (<75, ≥75 years) and treatment as fixed effect factors. BCVA, best corrected visual acuity; BL, baseline; ETDRS, Early Treatment Diabetic Retinopathy Study. LOCF, last observation carried forward; LS, least squares; SE, standard error.
BCVA change from baseline by brolucizumab 6 mg q12w or q8w dosing at Week 48

**HAWK**

**Matched Phase**

**Maintenance Phase**

**HARRIER**

**Matched Phase**

**Maintenance Phase**

**Full Analysis Set, LOCF. LS mean and SE estimates are based on an ANOVA model with baseline BCVA (≤55, 56–70, ≥71 letters), age (<75, ≥75 years), and treatment as fixed effect factors. BCVA assessments after start of alternative anti-VEGF treatment in the study eye are censored and imputed by the last value prior to start of this alternative treatment. Only subjects with at least one disease activity assessment are included. q12 = subjects with no identified q8 need by the investigator up to Week 48; q8 = subjects with at least one identified q8 need by the investigator up to Week 48. BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; LOCF, last observation carried forward; LS, least squares; q8w, 8-week dosing interval; q12w, 12-week dosing interval; SE, standard error; VEGF, vascular endothelial growth factor.**
BCVA change from baseline to Week 96: eyes with DA at Week 16 as assessed by investigators

Pooled analysis of HAWK & HARRIER patients with greater treatment need

Matched Phase

Maintenance Phase

Week
0 4 8 12 16 20

brolucizumab 6 mg +DA → n=161 (bro q8w)
aflibercept 2 mg +DA → n=226 (afl q8w)

Matched phase

Change from baseline in BCVA LS mean (SE), ETDRS letters

Week
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96

brolucizumab 6 mg (n = 161)
aflibercept 2 mg (n = 226)

Full Analysis Set, LOCF. LS mean and SE estimates are based on an ANOVA model with baseline BCVA (≤55, 56–70, ≥71 letters), age (<75, ≥75 years), and treatment as fixed effect factors. BCVA assessments after start of alternative anti-VEGF treatment in the study eye are censored and imputed by the last value prior to start of this alternative treatment. Only subjects with at least one disease activity assessment are included. Afl, aflibercept; BCVA, best-corrected visual acuity; bro, brolucizumab; DA, disease activity; ETDRS, Early Treatment Diabetic Retinopathy Study; LOCF, last observation carried forward; LS, least squares; q8w, 8-week dosing interval; SE, standard error; VEGF, vascular-endothelial growth factor.
CST change from baseline to Week 96: eyes with DA at Week 16 as assessed by investigators

Pooled analysis of HAWK & HARRIER patients with greater treatment need

Matched Phase

- brolucizumab 6 mg (n = 161)
- aflibercept 2 mg (n = 226)

Maintenance Phase

Δ = -60.4
p = 0.0002

Δ = -59.1
P < 0.0001

Δ = -37.4
p = 0.0060

Full Analysis Set, LOCF. LS mean and SE estimates are based on an ANOVA model with baseline CST-total (<400, ≥400 µm), age (<75, ≥75 years) and treatment as fixed effect factors. CST assessments after start of alternative anti-VEGF treatment in the study eye are censored and imputed by the last value prior to start of this alternative treatment.

CST, central subfield thickness; DA, disease activity; LS, least squares; SE, standard error; VEGF, vascular endothelial growth factor.
BCVA change from baseline to Week 96: eyes without DA at Weeks 16 and 20 as assessed by investigators

Full Analysis Set, LOCF. LS mean and SE estimates are based on an ANOVA model with baseline BCVA (≤55, 56–70, ≥71 letters), age (<75, ≥75 years), and treatment as fixed effect factors. BCVA assessments after start of alternative anti-VEGF treatment in the study eye are censored and imputed by the last value prior to start of this alternative treatment. Only subjects with at least one disease activity assessment are included. Afl, aflibercept; BCVA, best-corrected visual acuity; bro, brolucizumab; DA, disease activity; ETDRS, Early Treatment Diabetic Retinopathy Study; LOCF, last observation carried forward; LS, least squares; q8w, 8-week dosing interval; q12w, 12-week dosing interval; SE, standard error; VEGF, vascular endothelial growth factor
CST change from baseline to Week 96: eyes without DA at Weeks 16 and 20 as assessed by investigators

Pooled analysis of HAWK & HARRIER patients with lesser treatment need

Full Analysis Set, LOCF. LS mean and SE estimates are based on an ANOVA model with baseline CST-total (<400, ≥400 µm), age (<75, ≥75 years) and treatment as fixed effect factors. CST assessments after start of alternative anti-VEGF treatment in the study eye are censored and imputed by the last value prior to start of this alternative treatment.

CST, central subfield thickness; DA, disease activity; LS, least squares; SE, standard error; VEGF, vascular endothelial growth factor
Conclusions

HAWK and HARRIER: brolucizumab q12w/q8w non-inferior to aflibercept q8w in BCVA change from baseline to Week 48

Difference in BCVA change at Week 48 between brolucizumab q12w and q8w subgroups, based on masked investigators’ assessment of DA, reflects disease profiles with lesser or greater treatment need

Higher overall proportion of aflibercept- versus brolucizumab-treated eyes had DA at Week 16

Comparable BCVA outcomes for brolucizumab and aflibercept-treated eyes with greater treatment need from baseline to Week 96, with a numerical advantage for brolucizumab towards Week 96; greater CST reductions for brolucizumab versus aflibercept

BCVA and CST results comparable for brolucizumab and aflibercept-treated patients with lesser treatment need, with most brolucizumab patients on q12w regimen

BCVA, best-corrected visual acuity; CST, central subfield thickness; DA, disease activity; q8w, 8-week dosing interval; q12w, 12-week dosing interval